MitoRx Therapeutics

8 employees

MitoRx Therapeutics is a biotechnology company developing novel therapeutics that reverse mitochondrial dysfunction.

Basic info

Industry

biotechnology research

Sectors

Biotechnology

preclinical

mitochondrial myopathy

neurodegenerative disease

MTRX-1

muscular dystrophy

Duchenne

neuromuscular disease

first-in-target

MitoRx

first-in-class

new class

CBS-deficiency

Huntington's

hyperhomocysteinemia

mitochondrial disease

mitochondria

dementia

drug discovery

Therapeutics

Huntington's disease

DMD

biotech

rare disease

Date founded

2021

Funding rounds raised

MitoRx Therapeutics raised undisclosed on April 25, 2022

Investors: Future Planet Capital, UK Innovation & Science Seed Fund, Wren Capital LLP, Longevitytech.fund, Science Angel Syndicate, Oxford Technology Management and Fink Family Office

MitoRx Therapeutics raised undisclosed on March 1, 2019

Investors: Future Planet Capital